XII Medical

XII Medical, Inc. is a clinical-stage medical technology company based in Union City, California. Founded in 2017, the company specializes in innovative neuromodulation therapies aimed at treating obstructive sleep apnea (OSA). Their focus is on developing minimally invasive solutions that enhance patient compliance through streamlined surgical approaches and flexible implants.

The company's core platform features neuromodulation therapies designed specifically for OSA, which are currently in clinical-stage development and not available for sale. XII Medical conducts research and clinical trials to advance their technology, with a commitment to improving treatment options for the millions affected by OSA. The team is led by President and CEO Garrett Schwab, along with Executive Chairman Anthony Natale, M.D., and other key leaders in engineering and software. The company has successfully raised over $75 million in funding to support its mission.